Carol Gallagher, Pharm. D., is the immediate past president and CEO of Calistoga Pharmaceuticals which developed a portfolio of delta-selective PI3 kinase inhibitors for the treatment of patients with cancer and inflammatory diseases. Gallagher joined Calistoga Pharmaceuticals in September 2008. During her tenure as CEO, Gallagher raised $80M in venturing financing, securing top-tier investors Frazier Healthcare, Alta Partners, Three Arch Venutres, Amgen Ventures, Quogue Capital, and Latterell Venture Partners. She advanced their lead molecule, CAL-101, into full development and secured a successful exit with the $600M acquisition by Gilead Sciences in April, 2011.
Gallagher has over 22 years of experience in commercial and drug development roles at large and small biopharmaceutical companies. Notable during her career was her role as the Rituxan Development Team Leader at Idec Pharmaceuticals and after the merger, Biogen Idec.
Gallagher began her career in sales and marketing at Eli Lilly in 1989 and also held various commercial and development roles at Amgen, Agouron Pharmaceuticals, Pfizer, CancerVax, and Anadys. She attended Vanderbilt University and received Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky.